Takeshita, Masaru

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Rheumatology) (Shinanomachi)

Position

Instructor

 

Research Areas 【 Display / hide

  • Molecular biology

  • Immunology

  • Collagenous pathology/Allergology

Research Themes 【 Display / hide

  • 膠原病の病変組織に浸潤したリンパ球の解析, 

    2015.04
    -
    Present

  • 滑膜モデルの作成, 

    2015.04
    -
    Present

  • helper T細胞の分化, 

    2014.04
    -
    Present

  • 膠原病の糖タンパクバイオマーカー探索, 

    2013.04
    -
    Present

  • 各種膠原病のHLAとの関連に関する研究, 

    2013.04
    -
    Present

display all >>

 

Papers 【 Display / hide

  • Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis

    Kondo Y., Suzuki K., Inoue Y., Sakata K., Takahashi C., Takeshita M., Kassai Y., Miyazaki T., Morita R., Niki Y., Kaneko Y., Yasuoka H., Yamaoka K., Yoshimura A., Takeuchi T.

    Arthritis Research and Therapy (Arthritis Research and Therapy)  21 ( 1 )  2019.10

    ISSN  14786354

     View Summary

    © 2019 The Author(s). Background: Ultrasonography (US) can directly demonstrate joint inflammation, including grayscale (GS) signs of synovial hypertrophy and power Doppler (PD) techniques to demonstrate increased blood flow and vascularization. Recently, echogenicity, especially hypoechoic synovium, has also been associated with local inflammatory activity. However, only a few studies have demonstrated correlation between histopathologic and immunopathologic evaluation and US findings. The aim of this study was to clarify whether joint US findings including synovial hypertrophy, vascularity, and echogenicity can accurately characterize synovial pathophysiology in patients with active rheumatoid arthritis (RA). Methods: A total of 44 patients with RA were included, both treated (n = 25) and untreated (n = 19) and scheduled for US examination of the knee joint with synovial fluid (SF) aspiration and two treated patients also underwent synovial biopsy. US images were quantitatively analyzed using grayscale assessment of synovial hypertrophy and PD for vascularity and echogenicity. Levels of nine SF cytokines and growth factors were also measured. Results: Both US synovial hypertrophy and PD vascularity significantly correlated with SF inflammatory cytokine levels such as IL-6, IL-8, IL-1β and IL-10 in untreated patients. Angiogenic factors, including vascular endothelial growth factor (VEGF), only correlated with PD vascularity. In the treated patients, the associations between synovial hypertrophy and any cytokines were diminished, although synovial vascularity and echogenicity correlated with IL-6 and VEGF (p < 0.05). Histopathologic analysis revealed that hypoechogenicity of the synovium correlated with marked infiltration of lymphocytes and hypervascularity. Conclusions: We demonstrated the pathophysiological origins of US findings in the joint. The degree of US vascularity of the synovium correlated with local inflammatory cytokine levels and angiogenetic factors in patients with active RA. Synovial echogenicity, and not hypertrophy, correlated with inflammation, especially in treated patients with RA.

  • Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission

    Tasaki S., Suzuki K., Kassai Y., Takeshita M., Murota A., Kondo Y., Ando T., Nakayama Y., Okuzono Y., Takiguchi M., Kurisu R., Miyazaki T., Yoshimoto K., Yasuoka H., Yamaoka K., Morita R., Yoshimura A., Toyoshiba H., Takeuchi T.

    Nature Communications (Nature Communications)  9 ( 1 )  2018.12

     View Summary

    © 2018 The Author(s). Sustained clinical remission (CR) without drug treatment has not been achieved in patients with rheumatoid arthritis (RA). This implies a substantial difference between CR and the healthy state, but it has yet to be quantified. We report a longitudinal monitoring of the drug response at multi-omics levels in the peripheral blood of patients with RA. Our data reveal that drug treatments alter the molecular profile closer to that of HCs at the transcriptome, serum proteome, and immunophenotype level. Patient follow-up suggests that the molecular profile after drug treatments is associated with long-term stable CR. In addition, we identify molecular signatures that are resistant to drug treatments. These signatures are associated with RA independently of known disease severity indexes and are largely explained by the imbalance of neutrophils, monocytes, and lymphocytes. This high-dimensional phenotyping provides a quantitative measure of molecular remission and illustrates a multi-omics approach to understanding drug response.

  • Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis

    Takeshita Masaru, et al.

    Arthritis Research & Therapy 18 ( 112 )  2016.05

    Research paper (scientific journal), Joint Work, Accepted

  • Polarization diversity of human CD4(+) stem cell memory T cells

    Takeshita, Masaru, Suzuki, Katsuya, Kassai, Yoshiaki, Takiguchi, Maiko, Nakayama, Yusuke, Otomo, Yuki, Morita, Rimpei, Miyazaki, Takahiro, Yoshimura, Akihiko, Takeuchi, Tsutonnu

    CLINICAL IMMUNOLOGY 159 ( 1 ) 107 - 117 2015.07

    Research paper (scientific journal),  ISSN  1521-6616

  • Distinct Serum Protein Signature and Novel Biomarkers of primary Sjogren's Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis.

    Nishikawa, Ayumi, Suzuki, Katsuya, Kassai, Yoshiaki, Gotou, Yuumi, Miyazaki, Takahiro, Takiguchi, Maiko, Takeshita, Masaru, Murota, Atsuko, Morita, Rimpei, Yoshimura, Akihiko, Takeuchi, Tsutomu

    ARTHRITIS &amp; RHEUMATOLOGY 66   S1301 - S1302 2014.10

    Research paper (scientific journal),  ISSN  2326-5191

Papers, etc., Registered in KOARA 【 Display / hide

Research Projects of Competitive Funds, etc. 【 Display / hide

  • Single cell integrated analysis of antigen specificity and gene expression for the cure of autoimmune diseases

    2020.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 竹下 勝, Grant-in-Aid for Early-Career Scientists , Principal Investigator

  • 自己免疫疾患における新しい抗原提示機構とその意義について

    2016.04
    -
    2019.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 竹下 勝, Grant-in-Aid for Young Scientists (B), Principal Investigator